Analysts Set Expectations for OTCMKTS:MDNAF Q3 Earnings

Medicenna Therapeutics Corp. (OTCMKTS:MDNAF – Free Report) – Equities research analysts at HC Wainwright increased their Q3 2027 earnings estimates for Medicenna Therapeutics in a report issued on Wednesday, November 18th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.03) per share for the quarter, up from their prior estimate of ($0.04). The consensus estimate for Medicenna Therapeutics’ current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Medicenna Therapeutics’ Q4 2027 earnings at ($0.03) EPS, FY2027 earnings at ($0.13) EPS, Q1 2028 earnings at ($0.03) EPS, Q2 2028 earnings at ($0.03) EPS, Q3 2028 earnings at ($0.03) EPS, Q4 2028 earnings at ($0.03) EPS, FY2028 earnings at ($0.11) EPS, FY2029 earnings at ($0.08) EPS, FY2030 earnings at $0.12 EPS and FY2031 earnings at $0.27 EPS.

Medicenna Therapeutics Trading Up 12.0%

Shares of Medicenna Therapeutics stock opened at $0.14 on Friday. Medicenna Therapeutics has a 1-year low of $0.11 and a 1-year high of $1.30. The company’s fifty day simple moving average is $0.29 and its 200-day simple moving average is $0.37.

Medicenna Therapeutics (OTCMKTS:MDNAF – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01.

Key Headlines Impacting Medicenna Therapeutics

Investors following MDNAF have been watching these headlines:

  • Positive Sentiment: HC Wainwright raised its estimates across multiple future periods, projecting smaller losses in 2027–2029 and higher earnings in 2030–2031. It now forecasts FY2031 EPS of $0.27, up from $0.26, and FY2030 EPS of $0.12, up from $0.10. The improved projections could support sentiment about Medicenna’s longer-term earnings potential. Medicenna Therapeutics coverage
  • Neutral Sentiment: The near-term estimates remain loss-making, and the articles provide no new operating, financing, or clinical-trial developments to explain a fundamental change in the company’s outlook.

About Medicenna Therapeutics

(Get Free Report)

Medicenna Therapeutics is a Canadian biotechnology company focused on developing engineered cytokine-based immunotherapies for cancer. The company’s research centers on its “Superkine” platform, which is designed to modify cytokines—proteins involved in immune signaling—to direct immune activity toward tumors. Its development programs have included MDNA11, an engineered interleukin-2 designed to stimulate cancer-fighting T cells and natural killer cells, and MDNA55, an investigational treatment targeting receptors found on certain brain tumors.

See Also

Earnings History and Estimates for Medicenna Therapeutics (OTCMKTS:MDNAF)

Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.